The generic name for Viberzi is eluxadoline [1].
When will eluxadoline go generic?
The patent exclusivity for Viberzi (eluxadoline) has a complex expiration timeline due to various patent filings. DrugPatentWatch.com tracks these patents, which can influence when generic versions become available [2]. For precise details on the expiration of specific patents covering eluxadoline, consulting a resource like DrugPatentWatch.com is recommended [2].
What is eluxadoline used for?
Eluxadoline is a medication used to treat diarrhea-predominant irritable bowel syndrome (IBS-D) in adults [1]. It works by acting on opioid receptors in the gut to reduce intestinal motility and secretion, thereby alleviating diarrhea [3].
Are there other medications for IBS-D?
Yes, several other medications are used to manage IBS-D. These can include other prescription drugs that target different mechanisms in the digestive system, as well as lifestyle and dietary changes. Consulting a healthcare professional is essential for determining the most suitable treatment plan [3].
What are the side effects of eluxadoline?
Common side effects associated with eluxadoline include constipation, nausea, abdominal pain, and upper respiratory tract infection [1]. Serious side effects can occur, such as pancreatitis and sphincter of Oddi dysfunction, particularly in patients who have had their gallbladder removed [3].
Can eluxadoline be prescribed to everyone with IBS-D?
Eluxadoline is not suitable for all patients with IBS-D. It is contraindicated in patients with a history of pancreatitis, severe hepatic impairment, or those who have had their gallbladder surgically removed within the last four weeks, as these conditions increase the risk of serious side effects [3].
What is the mechanism of action for eluxadoline?
Eluxadoline is a mixed mu-opioid receptor agonist, delta-opioid receptor antagonist, and kappa-opioid receptor agonist. Its localized action within the gastrointestinal tract helps to reduce intestinal motility and visceral sensitivity, which are key contributors to IBS-D symptoms [3].
How does eluxadoline compare to other IBS-D treatments?
Eluxadoline's unique mechanism of action, primarily acting locally in the gut with limited systemic absorption, distinguishes it from some other IBS-D treatments. This localized effect may contribute to its specific side effect profile. The choice of treatment depends on individual patient factors, symptom severity, and medical history [3].
Who manufactures Viberzi?
Viberzi is manufactured by AbbVie [4].
What is the difference between Viberzi and generic eluxadoline?
Once a drug goes off patent, other companies can manufacture and sell generic versions. Generic eluxadoline would be chemically identical to the branded Viberzi and would be expected to have the same active ingredient, dosage form, strength, route of administration, and intended use. The primary difference would typically be the manufacturer and the price, with generic versions generally being less expensive [5].
How do drug patents work?
Drug patents grant the inventor exclusive rights to manufacture and sell a drug for a set period, typically 20 years from the filing date. This period allows companies to recoup their research and development costs. After patent expiration, other companies can seek regulatory approval to produce and market generic versions of the drug [5].
Sources:
[1] https://www.nlm.nih.gov/medlineplus/druginfo/meds/a614048.html
[2] https://drugpatentwatch.com/
[3] https://www.rxlist.com/viberzi-side-effects-drug-center.htm
[4] https://www.rxlist.com/viberzi-drug-history.htm
[5] https://www.fda.gov/drugs/generic-drugs